Starting July 1, 2026, Medicare beneficiaries may be able to get certain GLP‑1 prescription medications for weight loss for a flat $50 monthly copay through a short-term pilot called the Medicare GLP‑1 Bridge. The program runs through Dec. 31, 2027, and is intended to “bridge” to a possible longer-term approach in 2028.
Covered drugs include pill and injectable formulations approved for weight loss: Wegovy (pill and injectable), the KwikPen formulation of Zepbound, and the Foundayo pill. These drugs can be effective but are often expensive without coverage; current cash prices (even with some discounts) typically range from roughly $149 to $699 per month. KFF polling found about half of GLP‑1 users said the drugs were difficult to afford, with a quarter calling them “very difficult” to afford.
Who qualifies
– You must be enrolled in a Medicare Part D drug plan to participate.
– Eligibility is primarily clinical: people with a body mass index (BMI) of 35 or higher qualify automatically. Those with BMI 27 or higher may qualify if they have a qualifying condition such as heart disease or prediabetes. (About 40% of U.S. adults had obesity—BMI 30 or higher—based on CDC data.)
How it works
– The Bridge does not operate through your usual Part D plan’s standard pharmacy process. Instead, prescriptions require prior authorization through a central system run by Humana, a CMS contractor, using an existing Medicare drug program platform.
– Prescribers do not need to be enrolled Medicare providers to submit prior authorization requests. Once approved, the patient pays a $50 copay at the pharmacy.
– The $50 copay is fixed and does not increase with higher dosages, which many people need to maintain weight loss.
Benefits
– The predictable $50 copay could make these medications accessible to people who previously could not afford them. For many, that is far less than retail or some direct-to-consumer discounted prices.
– The Bridge creates a uniform copay regardless of dose level, which can be important because higher doses are commonly needed for sustained weight loss.
Caveats and downsides
– The $50 copay under the Bridge does not count toward a Part D plan deductible, nor toward the $2,100 annual out‑of‑pocket cap for prescription drugs.
– The Bridge is temporary; it ends Dec. 31, 2027. Many studies show people who stop GLP‑1 drugs often regain weight they lost while on them.
– People who receive Medicare’s low‑income subsidy (Extra Help) cannot apply that assistance to drugs obtained through the Bridge. For beneficiaries used to $5 or $10 copays, $50 can still be a major burden. As KFF’s Juliette Cubanski noted, $50 a month may be unaffordable for someone living on a modest Social Security check.
– If you already use a GLP‑1 for another covered indication (such as Type 2 diabetes, cardiovascular risk reduction, or sleep apnea), you will continue to receive it under your regular Part D plan and pay that plan’s price, which could be higher than the Bridge’s $50 copay. The same medication could therefore cost different amounts depending on why it’s prescribed.
Continuity for existing users
– If you started a GLP‑1 for weight loss before the Bridge began, you may still qualify. Your prescriber will need to attest that you met the clinical criteria when therapy began (for example, meeting the BMI threshold at treatment initiation even if your current BMI is lower).
Why it’s temporary and what’s next
– The administration originally proposed a two-step approach: start with a brief Bridge and then shift to a longer-term program that would move drug costs to insurers. A study suggested the long-term model could cost insurers billions in the first year. Not enough insurers signed on by the deadline, so CMS extended the Bridge to 18 months to gather more data and give insurers more time to negotiate.
– CMS has not released public projections of expected enrollment or cost; analysts say the Bridge could cost Medicare billions depending on uptake. The extension is intended to provide more information to insurers and policymakers before any permanent change is made.
Other considerations
– Many people who stop GLP‑1 therapy regain weight, which raises questions about how temporary coverage will affect long-term outcomes and costs.
– The program uses a centralized prior authorization process rather than individual Part D plans, which is an unusual setup for a Medicare drug benefit.
If you’re on Medicare and interested in a GLP‑1 for weight loss, confirm your Part D enrollment, discuss eligibility and prior authorization with your prescriber, and consider whether a $50 monthly copay (and the program’s temporary nature) fits your circumstances.